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Purpose.Toreport thevisualoutcome ofpenetratingkeratoplasty performedonthesympathizingeye inthreecases ofsympathetic
ophthalmitis. Methods. Interventional case series of three patients, diagnosed with sympathetic ophthalmitis, with corneal changes
in the form of band keratopathy and decompensation underwent penetrating keratoplasty to the sympathizing eye. They had each
sustainedpenetratingtraumaasachildandhadundergonepreviouscataractsurgeryandsuperﬁcialkeratectomy.Twopatientshad
undergone lamellar keratoplasty prior to this procedure. One patient had undergone trabeculectomy for glaucoma, and she was
on antiglaucoma medication. The preoperative visual acuity was 1/60 in the aﬀected eye of each patient. Penetrating keratoplasty
was performed in the sympathizing eye and the donor graft size was 7.50mm, and the host graft size was 7.25mm. Our patients
were immunosuppressed prior to the procedure to help prevent graft rejection. Result. At one year follow-up, a BCVA of 6/36
or better was achieved in all three patients. Postoperative examination of the fundus showed peripheral chorioretinal atrophy
with pigmentary changes at the macula, accounting for the limited vision. The grafts remain clear to date, and there has been
no recurrence of uveitis or rejection. Conclusion. Penetrating keratoplasty can be considered as a surgical option to restore useful
vision in a stable sympathizing eye in sympathetic ophthalmitis, and this depends on the extent of the pathology. However, these
cases require treatment with immunosuppressives to prevent graft rejection and to prolong graft survival.
1.Introduction
Sympathetic ophthalmia (SO) is a rare, bilateral granuloma-
tous inﬂammatory condition that follows penetrating ocular
injury or surgery. The sympathizing eye develops severe
inﬂammation, and this may be worse than the inﬂammation
in the exciting eye [1]. The course of the disease is often
progressive and some of the late anterior segment manifes-
tations such as cataract formation and corneal changes may
b ed u et or e a c t i v ea n dd e g e n e r a t i v ec h a n g e s .A p a r tf r o m
cataract extraction, the surgical outcome in SO, of other
types of anterior segment surgery have seldom been reported
[2, 3]. We have managed three patients with long-term
corneal changes that required penetrating keratoplasty to
improvevision.Toourknowledge,suchsurgicalintervention
to restore vision has not hitherto been reported. The aim of
this paper is to report the clinical course and the outcome of
the corneal grafts of these patients with SO.
2.CaseReports
2.1. Case 1. A 68-year-old female patient was referred to
the corneal service with a decompensated and opaque right
cornea with a vision of counting ﬁngers. She had sustained
penetrating trauma to her left eye with scissors at six years
of age, and this eye was enucleated a few months later. She
developed recurrent inﬂammation of the right eye, which
was treated with oral steroids. At the age of 30 years the
vision declined due to cataract formation, which was treated
by intracapsular cataract extraction the following year.
Prior to this she had undergone band keratopathy
removal with EDTA on a few occasions, as well as
one superﬁcial keratectomy and one lamellar keratoplasty
(8.5mm) (Table 1). Following this procedure her low-grade
uveitis recurred and the cornea developed bullous oedema,
and deposition of patchy band keratopathy. The BCVA
was CF in her only eye. Slit lamp biomicroscopy showed2 Journal of Ophthalmology
Table 1: This table shows the list of procedures before PK in the sympathising eye.
Surgery 1 Surgery 2 Surgery 3 Surgery 4
Case 1 Cataract surgery Superﬁcial keratectomy Lamellar keratoplasty Penetrating keratoplasty
Case 2 ICCE with trabeculectomy Lamellar keratoplasty Superﬁcial keratectomy Penetrating keratoplasty
Case 3 Cataract surgery Superﬁcial keratectomy Penetrating keratoplasty
(a) (b)
(c) (d)
(e) (f)
Figure 1: (a) Slit lamp biomicroscopy showing corneal decompensation and band keratopathy in patient 1. (b) Postoperative picture
showing clear corneal graft of the same patient. (c) Preoperative slit lamp biomicroscopy showing corneal degeneration in patient 2. (d)
Slit lamp biomicroscopy showing clear graft of patient 2. (e) Preoperative slit lamp biomicroscopy showing corneal changes in the form of
degeneration in patient 3. (f) Postoperative clear corneal graft in patient 3.
corneal decompensation and degenerative changes in the
formofbandkeratopathy(Figure 1(a)).Therewasnofundus
view. Ocular ultrasonography showed no evidence of retinal
detachment. The patient was counselled for the high risk of
graft failure and the potential risks of immunosuppressive
therapy. Mycophenolate, 1g twice a day was prescribed one
month prior to the procedure. A penetrating keratoplaty was
performed under general anaesthesia. The size of the donor
graft was 7.50mm (0.25mm bigger than the host trephine).
No postoperative complications were encountered during
the follow-up period. Her Postoperative immunosuppressive
regime consisted of MMF 1gram twice a day with a reducing
dose of oral prednisolone. The initial dose of prednisolone
was 40mg per day that was reduced by 5mg for each week,
until a 5mg daily maintenance dose was achieved. Mycophe-
nolate was stopped at eight months Postoperatively due to
sterile pyuria, and she is currently on prednisolone 5mg
daily and topical steroids twice a day. At one year follow-up
period, her BCVA was 6/18 and the graft remains clear to
date (Figure 1(b)). Postoperatively the fundus examination
showed a pale optic disc and chorioretinal scarring in the
retinal periphery and pigmentary changes at the macula
(Figure 2).
2.2. Case 2. A 74-year-old female was referred to the corneal
services for consideration of a penetrating keratoplasty in
her only eye. She had sustained injury to her right eye at
the age of 3-years. She developed sympathetic ophthalmitisJournal of Ophthalmology 3
Figure 2: Fundus photograph showing macular scarring and
peripheral chorioretinal changes.This was seen in all the three cases.
and the eye was enucleated at 24 years of age. She had
suﬀered ﬂare ups of inﬂammation on and oﬀ and at the age
of 52 underwent intracapsular cataract extraction, followed
by trabeculectomy in the same year. She developed band
keratopathy, for which she underwent lamellar keratoplasty
twice in 1993 and in the year 2000 (Table 1). She was
on oral prednisolone 5mg daily and topical brinzolamide.
Her visual acuity was 1/60 in her left eye, the cornea was
hazy due to degenerative changes (Figure 1(c)). Following
detailed counselling she underwent penetrating keratoplasty.
The host trephine was 7.25mm and the donor was 7.50mm.
Postoperatively, apart from topical steroids and topical
antibiotics, she was on oral prednisolone 10mg, and she
continued her antiglaucoma medication.
Atoneyearfollow-upherbestcorrectedvisualacuitywas
6/36 and she is on 5mg daily of oral prednisolone. There
were no Postoperative complications during this period
and the graft remains clear to date (Figure 1(d)). Fundus
examination showed pallor of the disc and peripheral chorio
-retinal scarring (Figure 2).
2.3. Case 3. A 27-year-old male sustained penetrating
t r a u m at oh i sr i g h te y ea sac h i l da t7y e a r so fa g e ,b u t
unlike the other two cases had undergone primary repair.
He developed sympathetic ophthalmia a few years later, and
this was managed with oral steroids. He had also undergone
cataract extraction to both eyes and used contact lenses to
correct his aphakia. Like our other two cases, he too had
undergone superﬁcial keratectomy for band keratopathy in
the sympathising eye. He was then oﬀered and underwent a
corneal graft, to the exciting right eye. This was performed
under immunosuppressive cover of mycophenolate 1g twice
a day along with 40mg of oral steroids which was then
reduced to the dose 500mg once a day and oral prednisolone
5mg once a day. He developed glaucoma in his right eye,
one year from the time of the graft and is on topical
with brinzolamide and latanoprost. On examination, one
year from the time of right corneal graft procedure, his
BCVA was 3/60 in his right eye and 1/60 in his left eye.
Anterior segment examination showed a clear right corneal
graft and corneal degenerative changes in the form of band
keratopathy and corneal decompensation in his left eye
(Figure 1(e)). Ultrasound examination showed the retina
to be attached and a single ﬂash ERG showed a normal
retinal response in his left eye. Penetrating keratoplasty was
performed on the sympathizing eye, with the donor graft
size of 7.50mm and the host was 7.25mm. Postoperatively
the mycophenolate was increased to 1g twice a day and was
also on 30mg oral prednisolone which was then tapered
by 5mg per week, and he is on the maintainance dose of
5mg. He was also on topical steroids and antibiotics. At
10 months follow-up his BCVA was 6/36 and his graft was
clear (Figure 1(e)). Fundus examination showed peripheral
chorioretinal atrophy with scarring at the macula (Figure 2).
3. Discussion
Long-term changes of SO aﬀect both the anterior and
posterior segment of the eye. Immunohistopathological
ﬁndings suggest that delayed hypersensitivity, mediated by
T cells, is involved in the pathogenesis of SO [4, 5].
Recurrences and low-grade inﬂammation are common.
The pathological changes observed in long-term SO are
aggravated by reactive and degenerative changes secondary
to chronic inﬂammation speciﬁcally in the anterior segment
oftheeye.Theprincipleposteriorsegmentchangescomprise
chorioretinal degeneration, macular degeneration, and optic
atrophy. On the long term, the anterior segment changes
include band keratopathy, development of cataract, corneal
oedema/bullous keratopathy, endothelial loss, iris atrophy,
and ciliary body atrophy and traction. The mechanisms
by which chronic inﬂammation damages the cornea, lens,
retina, and uveal tissue are complex and may be due to
the sustained and direct cytopathic action of inﬂammatory
mediators, free radicals, and proinﬂammatory cytokines [2,
6]. Further chronic use of oral steroids may contribute to
cataract development and cataract surgery may aggravate the
depletion of endothelial cell loss.
All three patients who were managed with penetrating
keratoplasty had several high-risk factors for graft failure.
Chronic uveitis and the presence of anterior synechiae are
known inﬂammatory status, antigen presenting cells that
may facilitate recognition of foreign antigens and increase
the chances of graft rejection are primed. Further, the risk of
graft failure was high in these patients as they all undergone
previous intraocular surgery, partial thickness corneal grafts,
and raised intraocular pressure all of which are all known to
increase graft failure rates [7–11].
All our patients had chronic inﬂammation for number
of years but were quiescent for at least six months preced-
ing surgery. Intraocular surgery can reactivate Intraocular
inﬂammation in eyes that had multiple episodes of chronic
uveitis [12], and this can impair graft survival. Although
penetratingkeratoplastyintheeyewithchronicuveitisorSO
has not been reported, cataract surgery in the sympathizing
and the exciting eye have been performed with good visual
outcome [2, 3], and these patients need additional anti-
inﬂammatory cover to control inﬂammation.4 Journal of Ophthalmology
Our patients carried a high risk of rejection but also
reactivation of Intraocular inﬂammation. The immune
mechanisms of graft rejection in SO are T-cell-mediated
delayed hypersensitivity reactions. The initial response after
antigen presentation in the case of endothelial surface
antigens is T-cell activation. This results in activation of the
proinﬂammatory cascade and destruction of endothelium,
mediated by the killer cells and other cytokine-mediated
cytotoxicity. Once the endothelium is completely destroyed
this antigen-driven response abates, and there is no further
inﬂammation. However in the case of SO initial antigen-
driven activationofTcellsmayfollowachronic course.Dur-
ing the chronic phase, that is nonantigen driven, nonspeciﬁc
T-cell activation, and activation of macrophages and other
myeloid cells can give rise to another phase of inﬂammation
and tissue damage. Therefore in our patients the therapeutic
target was to control antigen-driven T-cell response (related
to endothelial antigen and possibly antigens related to SO)
and nonspeciﬁc (related to chronic phase of SO) T-cell and
macrophage activation, inﬂammation and tissue damage.
During the immediate Postoperative period the factor of
surgical trauma-induced inﬂammation needs to be taken
into consideration.
To improve the chances of graft survival and to prevent
recurrence of Intraocular inﬂammation, T-cell modulator
is considered. Calcineurin inhibitors such as cyclosporine
or tacrolimus or mycophenolate mofetil (MMF) that can
modulate T-cell function and may control chronic uveitis
components and also improve graft survival.
Both calcineurin inhibitors cyclosporine [13, 14]a n d
tacrolimus have proven beneﬁcial in controlling uveitis
[15, 16] and increasing graft survival [17, 18]. However
the bioavailability of cyclosporine is highly variable and
diﬃcult to predict [19–22]. The pharmacokinetic properties
of cyclosporine can be signiﬁcantly aﬀected by age [19,
20], ethnicity [21, 22], variability of gastrointestinal milieu,
concomitant ingestion of certain foods [23]b i l eﬂ o wa n d
medications [24], and coexisting pathology such as diabetes
[22]. Similarly the absorption of tacrolimus is also highly
variable leading to varying blood concentration proﬁles and
peak blood or plasma concentrations being reached in 0.5 to
6h o u r s[ 25]. However bioavailability can vary from 5% to
67% with a mean of 29% [26].
Thepharmacokineticsofcyclosporineandtacrolimusare
complex and unpredictable with a narrow therapeutic index
unique to each patient, as well as variable absorption, distri-
butionandelimination makingtherapeuticdrugmonitoring
important [27].
At the time when our patients underwent surgery, MMF
h a db e e nr e p o r t e da sa ne ﬀective agent in both controlling
uveitis [28]a n dg r a f tr e j e c t i o n[ 17]. MMF has been suc-
cessfully used in the management of organ transplantation
and chronic uveitis with fewer side eﬀects [28, 29]. For these
reasons we elected to use MMF as an immunosuppressive
agent for two of our patients. Patient number two had
cardiomyopathyandwasagenerallyfrailpatientandhercar-
diologist advised against immunosuppressive medications.
Hence she was on 10mg of oral steroids. Patient number
three was already on mycophenolate from the time of his
initial graft procedure to the other eye. Mycophenolate was
stopped eight months Postoperatively in patient one, due to
sterile pyuria. None of our patients developed any ﬂare-up
of uveitis or graft rejection during the follow-up period, and
the grafts remain clear to date.
In future, biological agents may be considered to aid
in managing similar situations but currently the evidence
for the use is sporadic. Inﬂiximab has been reported to be
eﬀective in controlling chronic uveitis and Behcet’s disease
[30–32]. Although inﬂiximab has been successfully used in
the management of intestinal transplant rejection [33–35],
it has not been used in the management of corneal graft
rejection and the high incidence of side eﬀects is a concern
[36]. There are only a few isolated case reports regarding the
beneﬁcial use of biological agents for graft rejection [37].
To conclude, penetrating keratoplasty can be considered
a safe surgical option to restore useful vision in a stable
sympathising eye. Preoperative and Postoperative control of
inﬂammation with immunosuppressive agents is imperative
to prevent rejection in these high-risk cases.
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